Burstein HJ et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: A randomized phase II study. San Antonio Breast Cancer Symposium 2005;Abstract 4.
Burstein HJ et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. San Antonio Breast Cancer Symposium 2002;446. No abstract available
De Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: Metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005;69(Suppl 3):46-56. Abstract
Denduluri N et al. Effect of bevacizumab and chemotherapy on serum levels of sVCAM- 1 in patient with inf lammatory and locally advanced breast cancer. Proc ASCO 2005;Abstract 611.
Dent R, Clemons M. Adjuvant trastuzumab for breast cancer. BMJ 2005;331(7524):1035-6. No abstract available
Ewer MS et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23(31):7820-6. Abstract
Garcia AA et al. Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. Proc ASCO 2005;Abstract 5000.
Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005;Abstract 3.
Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presentation. ASCO 2005a. No abstract available
Miller KD et al. Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. San Antonio Breast Cancer Symposium 2002;36. No abstract available
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005b;23(4):792-9. Abstract
Perez EA et al. NCCTG N9831: May 2005 update. Presentation. ASCO 2005;Abstract 556.
Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005a. No abstract available
Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005b;353(16):1659-72. Abstract
Ramaswamy B, Shapiro CL. Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer. Clin Breast Cancer 2003;4(4):292-4. No abstract available
Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO 2005a. No abstract available
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2 positive breast cancer. N Engl J Med 2005b;353(16):1673-84. Abstract
Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract
Wedam SB et al. A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inf lammatory breast cancer. Proc ASCO 2004;Abstract 578.
Yang JC et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34. Abstract
Yang SX et al. Response in gene expression profile to bevacizumab treatment in patients with inf lammatory and locally advanced breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 2028.